Watson licenses Antares' gel for overactive bladders in US and Canada Print E-mail
By Olivia D'Orazio - ProactiveInvestors.com   
Monday, 11 July 2011 22:21
Watson Pharmaceuticals (NYSE:WPI) and Antares Pharma (AMEX:AIS) announced Monday they have signed a deal under which Watson will commercialize Antares' topical oxybutynin gel, currently under review by the FDA for the treatment of overactive bladder (OAB), in the U.S. and Canada.

Watson, which focuses on urology and women's health, will make milestone payments to Antares based on certain sales targets.

Focused on self-injection and topical gel-based medicines, Antares is also set to receive escalating royalties based on product sales in the US and Canada once the gel, which is marketed as Anturol, is launched.

Additional details of the agreement have not been disclosed.

"We are confident Watson will successfully market the positive attributes of this next generation OAB gel product to physicians and patients," said Antares president and CEO, Paul K. Wotton.

Anturol is a clear, odorless topical gel that, in phase three clinical trials, was shown to significantly reduce the number of OAB symptoms in patients. A new drug application for the product is currently under review by the FDA.

"The addition of Antares' oxybutynin gel product will strategically enhance our overactive bladder product portfolio," said Watson vice president of Global Brands, Fred Wilkinson.

"Additionally, this product will expand our product offering to the Urology and OB/GYN audiences."


Proactiveinvestors is a leading news organisation and event business with offices in New York, Sydney, Toronto and London. The Company is a publisher and is not registered with the US Securities Exchange Commission or Ontario Securities Commission. Please read our full terms and conditions here http://www.proactiveinvestors.com/pages/terms



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter